<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
                      "http://www.w3.org/TR/REC-html40/loose.dtd">
<HTML>
<HEAD>
<TITLE>extropians: statins top the list of cholesterol lowerers</TITLE>
<META NAME="Author" CONTENT="Doug Skrecky (oberon@vcn.bc.ca)">
<META NAME="Subject" CONTENT="statins top the list of cholesterol lowerers">
</HEAD>
<BODY BGCOLOR="#FFFFFF" TEXT="#000000">
<H1>statins top the list of cholesterol lowerers</H1>
<!-- received="Tue May  9 13:41:31 2000" -->
<!-- isoreceived="20000509194131" -->
<!-- sent="Tue, 9 May 2000 12:41:58 -0700 (PDT)" -->
<!-- isosent="20000509194158" -->
<!-- name="Doug Skrecky" -->
<!-- email="oberon@vcn.bc.ca" -->
<!-- subject="statins top the list of cholesterol lowerers" -->
<!-- id="Pine.GSO.4.21.0005091241370.18484-100000@vcn.bc.ca" -->
<STRONG>From:</STRONG> Doug Skrecky (<A HREF="mailto:oberon@vcn.bc.ca?Subject=Re:%20statins%20top%20the%20list%20of%20cholesterol%20lowerers&In-Reply-To=&lt;Pine.GSO.4.21.0005091241370.18484-100000@vcn.bc.ca&gt;"><EM>oberon@vcn.bc.ca</EM></A>)<BR>
<STRONG>Date:</STRONG> Tue May 09 2000 - 13:41:58 MDT
<P>
<!-- next="start" -->
<UL>
<LI><STRONG>Next message:</STRONG> <A HREF="2710.html">Ken Clements: "Re: Our friend Sasha Chislenko is dead"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="2708.html">Brian D Williams: "Re: Our friend Sasha Chislenko is dead."</A>
<!-- nextthread="start" -->
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#2709">[ date ]</A>
<A HREF="index.html#2709">[ thread ]</A>
<A HREF="subject.html#2709">[ subject ]</A>
<A HREF="author.html#2709">[ author ]</A>
</UL>
<HR NOSHADE><P>
<!-- body="start" -->
<P>
Authors
<BR>
&nbsp;&nbsp;Bucher HC.  Griffith LE.  Guyatt GH.
<BR>
Institution
<BR>
&nbsp;&nbsp;Medizinsche Universitats-Poliklinik, Kantonsspital Basel, Basel,
<BR>
&nbsp;&nbsp;<A HREF="mailto:Switzerland.bucher@ubaclu.ubibas.ch?Subject=Re:%20statins%20top%20the%20list%20of%20cholesterol%20lowerers&In-Reply-To=&lt;Pine.GSO.4.21.0005091241370.18484-100000@vcn.bc.ca&gt;">Switzerland.bucher@ubaclu.ubibas.ch</A>
<BR>
Title
<BR>
&nbsp;&nbsp;Systematic review on the
<BR>
&nbsp;&nbsp;risk and benefit of different
<BR>
&nbsp;&nbsp;cholesterol-lowering interventions.
<BR>
Source
<BR>
&nbsp;&nbsp;Arteriosclerosis, Thrombosis &amp; Vascular Biology.  19(2):187-95, 1999 Feb.
<BR>
Abstract
<BR>
&nbsp;&nbsp;Meta-analyses have investigated the efficacy of
<BR>
&nbsp;&nbsp;cholesterol-lowering interventions in relation to the
<BR>
&nbsp;&nbsp;underlying risk of coronary heart disease and
<BR>
&nbsp;&nbsp;the extent and duration of cholesterol reduction. We
<BR>
&nbsp;&nbsp;systematically reviewed
<BR>
&nbsp;&nbsp;the efficacy of antilipidemic interventions on major
<BR>
&nbsp;&nbsp;mortality outcomes in relation to drug classes. We searched MEDLINE and
<BR>
&nbsp;&nbsp;EMBASE from 1966 through October 1996 for randomized, controlled trials of
<BR>
&nbsp;&nbsp;any cholesterol-lowering interventions reporting mortality data. We included
<BR>
&nbsp;&nbsp;59 trials involving 85 431 participants in the intervention
<BR>
&nbsp;&nbsp;and 87 729 participants in the control groups. We pooled
<BR>
&nbsp;&nbsp;these trials into 7 pharmacological categories of
<BR>
&nbsp;&nbsp;cholesterol-lowering interventions: statins (13 trials), fibrates (12
<BR>
&nbsp;&nbsp;trials), resins (8 trials), hormones (8 trials), niacin acid (2 trials), n-3
<BR>
&nbsp;&nbsp;fatty acids (3 trials), and dietary interventions (16 trials). Of
<BR>
&nbsp;&nbsp;the cholesterol-lowering interventions, only statins showed
<BR>
&nbsp;&nbsp;a large and statistically significant reduction in mortality from coronary
<BR>
&nbsp;&nbsp;heart disease (risk ratio, 0.66; 95% confidence interval
<BR>
&nbsp;&nbsp;[CI], 0.54 to 0. 79) and from all causes (risk ratio, 0.75;
<BR>
&nbsp;&nbsp;95% CI, 0.65 to 0.86). For both all-cause and cardiovascular mortality,
<BR>
&nbsp;&nbsp;the difference between statins and the
<BR>
&nbsp;&nbsp;combined estimate of the other classes of
<BR>
&nbsp;&nbsp;agents was unlikely to be due to chance (P&lt;0.02 for both comparisons).
<BR>
&nbsp;&nbsp;Meta-regression analysis demonstrated that variability in results across
<BR>
&nbsp;&nbsp;trials could be largely explained on the basis of
<BR>
&nbsp;&nbsp;differences in the magnitude of cholesterol reduction.
<BR>
&nbsp;&nbsp;Statins have the largest effect on the
<BR>
&nbsp;&nbsp;reduction of cardiovascular and all-cause mortality, and this result
<BR>
&nbsp;&nbsp;recommends their use in preference to other
<BR>
&nbsp;&nbsp;antilipidemic agents. The greater effect of statins is
<BR>
&nbsp;&nbsp;likely due to the larger reduction in cholesterol.
<BR>
<P><!-- body="end" -->
<HR NOSHADE>
<UL>
<!-- next="start" -->
<LI><STRONG>Next message:</STRONG> <A HREF="2710.html">Ken Clements: "Re: Our friend Sasha Chislenko is dead"</A>
<LI><STRONG>Previous message:</STRONG> <A HREF="2708.html">Brian D Williams: "Re: Our friend Sasha Chislenko is dead."</A>
<!-- nextthread="start" -->
<!-- reply="end" -->
<LI><STRONG>Messages sorted by:</STRONG> 
<A HREF="date.html#2709">[ date ]</A>
<A HREF="index.html#2709">[ thread ]</A>
<A HREF="subject.html#2709">[ subject ]</A>
<A HREF="author.html#2709">[ author ]</A>
</UL>
<!-- trailer="footer" -->
<HR NOSHADE>
<P>
<SMALL>
<EM>
This archive was generated by <A HREF="http://www.hypermail.org/">hypermail 2b29</A> 
: <EM>Thu Jul 27 2000 - 14:10:56 MDT</EM>
</EM>
</SMALL>
</BODY>
</HTML>
